Telework helps FDA compete for scientists. What if it’s no longer an option?
STAT+ May 11, 2023 Catalyst CEO and Founder Nancy Bradish [...]
HHS Floats Trio of Drug Pricing Models, Some More Ambitious Than Others
AISHealth.com - February 23, 2023 Jeff Myers, Catalyst’s Senior [...]
Rare Disease Week: Marking the 40th anniversary of the Orphan Drug Act
By Anne McNickle, VP - Research & Communications, Catalyst Can [...]
CMS sends roses to Sickle Cell Patients; but will the rest of Cell and Gene Therapy get the thorns?
By Jeff Myers, Senior Vice President, Reimbursement Strategy and Market Access, [...]
Catalyst’s Nancy Myers Co-Moderates Alliance for a Stronger FDA Webinar Featuring FDA Deputy Commissioner Andi Fristedt
Catalyst's Nancy Myers participated in an Alliance for a Stronger [...]
Catalyst is going to JP Morgan; Jeff Myers will speak on a panel at Biotech Showcase Jan. 10 on the impact of the IRA on innovation.
If you'd like to connect, shoot us an email.
Former FDA Chief Counsel Elizabeth Dickinson Hailed For Her Expertise, Warmth and Mentorship
The Pink Sheet - September 27, 2022 In an article [...]
FDA User Fee Programs Reauthorized: FDA’s CBER Is A Clear Winner
Pharmaceutical Online/Cell & Gene/Bioprocess Online – October 6, 2022 PDUFA [...]
Catalyst will be participating in the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa in Carlsbad, CA from October 11-13, 2022.
Shoot us an email and let’s catch up.
FDAnews Webinar: On Challenges Facing the New FDA Commissioner
During her panel for FDAnews, Nancy Myers highlighted impending challenges [...]